Prevention of Asthma Relapse After Discharge From Emergency (PARADE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00326053
Recruitment Status : Completed
First Posted : May 16, 2006
Last Update Posted : January 24, 2011
Information provided by:

May 12, 2006
May 16, 2006
January 24, 2011
May 2006
Not Provided
Time to first asthma relapse
Same as current
Complete list of historical versions of study NCT00326053 on Archive Site
  • Mean use of reliever medication
  • Asthma Control Questionnaire (ACQ) score
  • Complete AE and SAE collection
Same as current
Not Provided
Not Provided
Prevention of Asthma Relapse After Discharge From Emergency
A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Drug: Budesonide/formoterol
Other Name: Symbicort
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2007
Not Provided

Inclusion Criteria:

  • 18 - 65 years of age
  • Presenting at a study emergency department with an asthma exacerbation

Exclusion Criteria:

  • Admission to hospital
  • Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Gloria Jordana, MD AstraZeneca
Principal Investigator: Brian Rowe, MD University of Alberta
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP